...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current medical research and opinion >Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan
【24h】

Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan

机译：真实世界的证据表明，患者在失眠症患者中的安全性和有效性概况：日本营销后贩卖药物使用结果的分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Global Phase III trials of suvorexant showed no obvious differences in the safety and efficacy profile of suvorexant between elderly and non-elderly patients. However, the clinical profile of suvorexant in elderly patients with comorbidities in a real-world setting was not evaluated. To further understand the safety and efficacy profile of suvorexant in elderly patients with insomnia in a daily clinical practice setting, we conducted a sub-group analysis of the post-marketing drug-use results survey. Methods: Patients with insomnia who were treated with suvorexant for the first time were divided into three groups: group-1 ( = 65 years and = 75 years, N = 1028). Results: The incidence of overall adverse drug reactions (ADRs) were 11.28% (N = 168), 8.63% (N = 63), and 8.17% (N = 84) in group-1, -2, and -3, respectively. The ADRs most commonly observed in this survey were somnolence, insomnia, and dizziness, with no new safety concerns or differences in safety issues found. The numbers of patients in group-1, -2, and -3 who visited internal medicine departments were: 690 patients (46.3%), 521 patients (71.4%), and 793 patients (77.1%), respectively. The percentage of patients who were deemed to have "improved", based on the patient's self-assessment and their physician's assessment, was 70-75% of patients in all groups. Conclusion: These results reveal the safety and efficacy profile of suvorexant in elderly patients who often have various and multiple comorbidities and were treated in a daily clinical practice setting.
机译：目的：Suvorexant的全球III期试验表明，老年人和非老年患者的Suvorexant安全性和功效概况没有明显差异。然而，未评估在真实世界环境中的患者在老年人患者中的临床剖面。为了进一步了解日期临床实践环境中老年人失眠患者的Suvorexant的安全性和功效谱，我们对营销后的药物使用结果调查进行了分析。方法：第一次用Suvorex治疗的失眠患者分为三组：1（= 65岁，= 75岁，N = 1028）。结果：总不利药物反应（ADR）的发生率分别为11.28％（n = 168），8.63％（n = 63），分别为-1，-2和-3的8.17％（n = 84） 。在本调查中最常见的ADR是嗜睡，失眠和头晕，没有发现的安全问题或发现的差异。访问内科部门的1，-2和-3患者的数量分别为：690名患者（46.3％），521名患者（71.4％）和793名患者（77.1％）。基于患者的自我评估及其医生的评估，被视为“改进”的患者的百分比为70-75％的患者。结论：这些结果揭示了往往具有各种和多种合并症的老年患者的Suvorexant的安全性和有效性曲线，并在日常临床实践环境中进行治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号